Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FTEON
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-PIEZO1-MMAE
|
|||||
| Synonyms |
AntiPIEZO1 MMAE
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Esophageal squamous cell carcinoma [ICD11:2B71]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-PIEZO1 mAb
|
Antibody Info | ||||
| Antigen Name |
Piezo-type mechanosensitive ion channel component 1 (PIEZO1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.00% (Day 27) | High PIEZO1 expression (PIEZO1+++) | ||
| Method Description |
1 x107 TE1 cells were suspended in Matrigel and injected subcutaneously in the right armpit. The treatment of AntiPIEZO1MMAE or control reagents started when the tumor volume reached 300mm3. Treatments for each group were given every 3 days in total four times.
|
||||
| In Vivo Model | Esophageal squamous cell carcinoma CDX model | ||||
| In Vitro Model | Esophageal squamous cell carcinoma | Esophageal squamous cell carcinoma cells | Homo sapiens | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.